Key Dates

Related Announcements

• July 10, 2021 - Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional). See NOFO PAR-21-163.

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

National Eye Institute (NEI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Center for Complementary and Integrative Health (NCCIH)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Behavioral and Social Sciences Research (OBSSR)

Purpose

The purpose of this notice is to inform applicants of an extension to PAR-21-163 “Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)”. The following application due dates have been added: July 15, 2024, AIDS Application Due Date: August 19, 2024, Expiration Date: August 20, 2024. Changes to this notice of funding opportunity (NOFO) are shown below.

Currently Reads:

Part 1. Overview Information

Key Dates:

Expiration Date: May 08, 2024

Modified to Read:

Part 2. Overview Information

Key Dates

Expiration Date: August 20, 2024

All other aspects of this NOFO remain unchanged.

Inquiries

Please direct all inquiries to:

Chris Boshoff, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email: chris.boshoff@nih.gov